Ginkgo Bioworks Holdings (DNA) Share-based Compensation (2020 - 2026)

Ginkgo Bioworks Holdings (DNA) has reported Share-based Compensation for 7 consecutive years, with $7.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Share-based Compensation fell 66.28% year-over-year to $7.6 million; the trailing twelve-month figure through Jun 2026 stood at $62.6 million (down 15.99% YoY), and the FY2025 full-year result was $81.5 million, down 27.41% from the prior year.
• Share-based Compensation retreated to $7.6 million in Q2 2026 per DNA's latest filing, from $15.9 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $652.8 million in Q1 2022 and bottomed at $7.6 million in Q2 2026.
• Historically, Share-based Compensation has averaged $132.1 million across 5 years, with a median of $39.5 million in 2024.
• The widest YoY moves for Share-based Compensation: up 553138.14% in 2022, down 93.2% in 2022.
• Over 5 years, Share-based Compensation stood at $108.2 million in 2022, then sank by 60.4% to $42.8 million in 2023, then slumped by 52.0% to $20.6 million in 2024, then rose by 2.27% to $21.0 million in 2025, then tumbled by 63.88% to $7.6 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $7.6 million, $15.9 million, and $21.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.